BridgeBio Pharma Inc

NASDAQ:BBIO   3:30:47 PM EDT
63.22
+1.89 (+3.08%)
Products

Bridgebio Pharma Receives FDA Fast Track Designation For Encaleret For The Treatment Of Autosomal Dominant Hypocalcemia Type 1

Published: 06/01/2021 13:14 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1.